Literature DB >> 29723091

Well-Founded Recommendations for Radioactive Iodine Treatment of Differentiated Thyroid Cancer Require Balanced Study of Benefits and Harms.

Mark Tulchinsky1, Richard P Baum1, K G Bennet1, Leonard M Freeman1, Ian Jong1, Kalevi Kairemo1, Carol S Marcus1, Renee M Moadel1, Paritosh Suman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29723091     DOI： 10.1200/JCO.2018.78.5972

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies.

Authors:  Frederik A Verburg; Martha Hoffmann; Ioannis Iakovou; Mark W Konijnenberg; Jasna Mihailovic; Pablo Minguez Gabina; Petra Petranović Ovčariček; Cristoph Reiners; Alexis Vrachimis; Slimane Zerdoud; Luca Giovanella; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03       Impact factor: 9.236

2.  Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.

Authors:  Xiaoran Mei; Xiaoqin Yao; Fang Feng; Weiwei Cheng; Hui Wang
Journal:  BMC Cancer       Date:  2021-05-13       Impact factor: 4.430

3.  Comparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer.

Authors:  Kalevi Kairemo; Aki Kangasmäki; Hee-Seung Bom
Journal:  Chonnam Med J       Date:  2019-01-25

Review 4.  Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.

Authors:  Einat Slonimsky; Mark Tulchinsky
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.